Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Cell Rep Med. 2020 Dec 5;2(1):100164. doi: 10.1016/j.xcrm.2020.100164. eCollection 2021 Jan 19.
Convalescent plasma (CP) is widely used to treat COVID-19, but without formal evidence of efficacy. Here, we report the beneficial effects of CP in a severely ill COVID-19 patient with prolonged pneumonia and advanced chronic lymphocytic leukemia (CLL), who was unable to generate an antiviral antibody response of her own. On day 33 after becoming symptomatic, the patient received CP containing high-titer (ID > 5,000) neutralizing antibodies (NAbs), defervesced, and improved clinically within 48 h and was discharged on day 37. Hence, when present in sufficient quantities, NAbs to SARS-CoV-2 have clinical benefit even if administered relatively late in the disease course. However, analysis of additional CP units revealed widely varying NAb titers, with many recipients exhibiting endogenous NAb responses far exceeding those of the administered units. To obtain the full therapeutic benefits of CP immunotherapy, it will thus be important to determine the neutralizing activity in both CP units and transfusion candidates.
恢复期血浆（CP）被广泛用于治疗 COVID-19，但缺乏疗效的正式证据。在这里，我们报告了 CP 对一位患有长期肺炎和晚期慢性淋巴细胞白血病（CLL）的重症 COVID-19 患者的有益作用，该患者自身无法产生抗病毒抗体反应。在出现症状后的第 33 天，该患者接受了含有高滴度（ID > 5000）中和抗体（NAb）的 CP，在 48 小时内退热并在临床上得到改善，于第 37 天出院。因此，当 SARS-CoV-2 的 NAb 数量足够多时，即使在疾病过程中相对较晚给予，也具有临床益处。然而，对其他 CP 单位的分析显示 NAb 滴度差异很大，许多接受者表现出的内源性 NAb 反应远远超过给予单位的反应。因此，为了获得 CP 免疫疗法的全部治疗益处，确定 CP 单位和输血候选者中的中和活性将非常重要。
Zotero 插件
